TY - JOUR
T1 - Upshaw-schulman syndrome revisited
T2 - A concept of congenital thrombotic thrombocytopenic purpura
AU - Kinoshita, S.
AU - Yoshioka, A.
AU - Park, Y. D.
AU - Ishizashi, H.
AU - Konno, M.
AU - Funato, M.
AU - Matsui, T.
AU - Titani, K.
AU - Yagi, H.
AU - Matsumoto, M.
AU - Fujimura, Y.
N1 - Funding Information:
This work was supported, in part, by research grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (to Y.F.) and from the Ministry of Health and Welfare of Japan for Blood Coagulation Abnormalities H11-02 (to Y.F.). We are indebted to Dr. J. Evan Sadler at the Howard Hughes Medical Institute and the Washington Uni- versity School of Medicine for critical reading and valuable comments in preparing this manuscript.
PY - 2001
Y1 - 2001
N2 - Upshaw-Schulman syndrome (USS) is a congenital bleeding disorder characterized by repeated episodes of thrombocytopenia and microangiopathic hemolytic anemia that respond to infusions of fresh frozen plasma. Inheritance of USS has been thought to be autosomal recessive, because 2 siblings in the same family are often affected but their parents are asymptomatic. Recently, chronic relapsing thrombotic thrombocytopenic purpura (CR-TTP), reported almost exclusively in adults, was shown to be caused by inherited or acquired deficiency in the activity of a plasma von Willebrand factor-cleaving protease (vWF-CPase).The pathogenesis of USS is unknown, and a relationship between CR-TTP and USS has not been reported. We studied 3 unrelated USS patients (ST, SY, and KI) who presented with severe indirect neonatal hyperbilirubimenia. All 3 patients had undetectable vWF-CPase activity, and the inhibitors to vWF-CPase were all negative. In their parents with no clinical symptoms, vWF-CPase activities as a percentage of control samples (mother/father) were 17/20 for ST, 60/45 for SY, and 36/5.6 for KI. Thus, USS and vWF-CPase activity appear to be coinherited as autosomal recessive traits. Transfusion of fresh frozen plasma in 2 patients (ST and SY) resulted in the expected maximal increment of approximately 7% to 8% in vWF-CPase activity at 1 to 4 hours, but the levels became less than 3% within 2 days. After this decrease, platelet counts increased, plateaued in the normal range at 10 to 12 days, and declined thereafter. Thus, the 2 to 3 weeks of therapeutic benefit from plasma infusions will be discussed in relation to the intravascular lifetime of vWF-CPase.
AB - Upshaw-Schulman syndrome (USS) is a congenital bleeding disorder characterized by repeated episodes of thrombocytopenia and microangiopathic hemolytic anemia that respond to infusions of fresh frozen plasma. Inheritance of USS has been thought to be autosomal recessive, because 2 siblings in the same family are often affected but their parents are asymptomatic. Recently, chronic relapsing thrombotic thrombocytopenic purpura (CR-TTP), reported almost exclusively in adults, was shown to be caused by inherited or acquired deficiency in the activity of a plasma von Willebrand factor-cleaving protease (vWF-CPase).The pathogenesis of USS is unknown, and a relationship between CR-TTP and USS has not been reported. We studied 3 unrelated USS patients (ST, SY, and KI) who presented with severe indirect neonatal hyperbilirubimenia. All 3 patients had undetectable vWF-CPase activity, and the inhibitors to vWF-CPase were all negative. In their parents with no clinical symptoms, vWF-CPase activities as a percentage of control samples (mother/father) were 17/20 for ST, 60/45 for SY, and 36/5.6 for KI. Thus, USS and vWF-CPase activity appear to be coinherited as autosomal recessive traits. Transfusion of fresh frozen plasma in 2 patients (ST and SY) resulted in the expected maximal increment of approximately 7% to 8% in vWF-CPase activity at 1 to 4 hours, but the levels became less than 3% within 2 days. After this decrease, platelet counts increased, plateaued in the normal range at 10 to 12 days, and declined thereafter. Thus, the 2 to 3 weeks of therapeutic benefit from plasma infusions will be discussed in relation to the intravascular lifetime of vWF-CPase.
UR - http://www.scopus.com/inward/record.url?scp=0035408661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035408661&partnerID=8YFLogxK
U2 - 10.1007/BF02982558
DO - 10.1007/BF02982558
M3 - Article
C2 - 11530798
AN - SCOPUS:0035408661
SN - 0925-5710
VL - 74
SP - 101
EP - 108
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 1
ER -